Индуцированная таксанами периферическая нейропатия: механизм развития и фармакогенетические факторы
- Авторы: Шестакова Л.В.1, Сычев Д.А.1, Поддубная И.В.1
-
Учреждения:
- ФГБОУ ДПО РМАНПО
- Выпуск: Том 20, № 1 (2018)
- Страницы: 60-63
- Раздел: Статьи
- URL: https://journals.rcsi.science/1815-1434/article/view/27172
- ID: 27172
Цитировать
Полный текст
Аннотация
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Любовь Владимировна Шестакова
ФГБОУ ДПО РМАНПО
Email: Lyubov_shestakova@list.ru
аспирант каф. онкологии 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
Дмитрий Алексеевич Сычев
ФГБОУ ДПО РМАНПО
Email: dimasychev@mail.ru
д-р мед. наук, проф., зав. каф. клинической фармакологии и терапии 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
Ирина Владимировна Поддубная
ФГБОУ ДПО РМАНПОакад. РАН, д-р мед. наук, проф., зав. каф. онкологии 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
Список литературы
- Тюляндин С.А., Гарин А.М., Горбунова В.А. Таксаны - новые противоопухолевые препараты растительного происхождения с уникальным механизмом действия. Вестн. РОНЦ им. Н.Н.Блохина РАМН. 1993; 4 (S): 96-101.
- Roriguez-Antona C. Pharmacogenomics of paclitaxel. Pharmacogenomics 2010; 11 (5): 621-3.
- Krens S.D, McLeod H.L, Hertz D.L. Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. Pharmacogenomics 2013; 14 (5): 555-74.
- Jabir S, Naidu R, Azrif Bin Ahmad Annuar M et al. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Pharmacogenomics 2012; 13 (16): 1979-88.
- Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И.Переводчиковой, В.А.Горбуновой. 4-е изд., расшир. и доп. М: Практическая медицина, 2015
- Kus T, Aktas G, Emin Kalender M et al. Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. OncoTargets and Therapy 2016: 9: 5073-9.
- Tanabe Y, Hashimoto K, Shimizu C et al. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 2013; 132-8.
- Eckhoff L, Knoop A.S, Jensen M.B et al. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat 2013; 142: 109-18.
- Leskelä S, Jara C, Leandro-García L.J. et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 2011; 11: 121-9.
- Корман Д.Б. Мишени и механизмы действия противоопухолевых препаратов. М.: Практическая медицина, 2014; с. 132, 135
- Addington J, Freimer M. Chemotherapy-induced peripheral neuropathy: an update on the current understanding [version 1; referees: 2 approved]. F1000Research 2016; 5 (F1000 Faculty Rev): 1466.
- Mironov S.L, Ivannikov M.V, Johansson M. [Ca2+] i signaling between mitochondria and endoplasmic reticulum in neurons is regulated by microtubules. From mitochondrial permeability transition pore to Ca2+-induced Ca2+ release. J Biol Chem 2005; 280: 715-21.
- Canta A, Pozzi E, Alda Carozzi V. Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN). Toxics 2015; 3: 198-215.
- Flatters S.J, Bennett G.J. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006; 122 (3): 245-57.
- Evtodienko Y.V, Teplova V.V, Sidash S.S et al. Microtubule-active drugs suppress the closure of the permeability transition pore in tumour mitochondria. FEBS Lett 1996; 39: 86-8.
- Kidd J, Pilkington M, Schell M et al. Paclitaxel affects cytosolic Ca2+ signals by opening the mitochondrial permeability transition pore. J Biol Chem 2002; 277: 6504-10.
- Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
- Baines C.P. The molecular composition of the mitochondrial permeability transition pore. J Mol Cell Cardiol 2009; 46: 850-7.
- Carré M et al. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem 2002; 277 (37): 33664-9.
- Новиков В.Е., Левченкова О.С. Митохондриальные мишени для фармакологической регуляции адаптации клетки к воздействию гипоксии. Обзоры по клинической фармакологии и лекарственной терапии. 2014; 12 (2): 28-33.
- Bernardi P, Krauskopf A, Basso E et al. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J 2006; 273: 2077-99.
- Rodi D, Janes R, Sanganee H et al. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J Mol Biol 1999; 285: 197-203.
- Peters C.M et al. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 2007; 1168: 46-59.
- Jabir S, Naidu R, Azrif Bin Ahmad Annuar M et al. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Pharmacogenomics 2012; 13 (16): 1979-88.
- Hertz D.L. Germline pharmacogenetics of paclitaxel for cancer treatment. Pharmacogenomics 2013; 14 (9): 1065-84.
- Baker S.D, Verweij J, Cusatis G.A et al. Pharmacogenetic Pathway Analysis of Docetaxel Elimination. Clin Pharmacol Ther 2009; 85 (2): 155-63.
- Li Jing. Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. Pharmacogenomics and Personalized Medicine 2011; 11-33.
- Bosch T.M, Huitema A.D, Doodeman V.D. et al. Pharmacogenetic screening of CYP3A and ABCB1in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 2006; 5786-93.
- Tran A, Jullien V, Alexandre J et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006; 79 (6): 570-80.
- Baker S.D, Verweij J, Cusatis G.A. et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2009; 85 (2): 155-63.
- Gréen H, Soderkvist P, Rosenberg P et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 2009; 104 (2): 130-7.
- Henningsson A, Marsh S, Loos W.J et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005; 11(22): 8097-104.
- Bergmann T.K, Brasch-Andersen C, Gréen H et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2011; 11 (2): 113-20.
- Fransson M.N, Gréen H, Litton J.E, Friberg L.E. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanismbased model. Drug Metab Dispos 2011; 39 (2): 247-55.
- Marsh S, Somlo G, Li X et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 2007; 7 (5): 362-5.
- Hertz D.L. Roy S, Motsinger-Reif A.A et al. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 2013; 24 (6): 1472-8.
- Hertz D.L. Motsinger-Reif A.A, Drobish A et al. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 2012; 134 (1): 401-10.
- Abraham J.E, Guo Q, Dorling L et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res 2014; 20 (9): 2466-75.
- Rizzo R, Spaggiari F, Indelli M et al. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res Treat 2010; 124 (2): 593-8.
- Chang H, Rha S.Y, Jeung H.C et al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 2009; 20 (2): 272-7.